John L. Marshall, MD, on Accessibility of Precision Medicine

Video

The expert from the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.

In an article published in the journal Oncology®, John L. Marshall, MD, of the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.

“Cancer care can no longer be a luxury item, only for the rich. We must work toward wide access,” Marshall wrote. “Opening markets through collaborative science will secure the return on investment for our business partners, and secure our progress toward finding the cures for cancer.”

In an interview with CancerNetwork®, Marshall spoke about his paper further and why precision medicine will change global cancer care for decades to come.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

Marshall JL. The Prospective Incorporation of Molecular Profiling Will Transform Global Cancer Care. Oncology. https://www.cancernetwork.com/view/the-prospective-incorporation-of-molecular-profiling-will-transform-global-cancer-care

Related Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.